Artivion, Inc.

NYSE:AORT

Medical - Devices

Healthcare
$18.54 -0.52%

-$0.11 today

Market cap
$904.56M
Beta
1.26
P/E (TTM)
86.7
EPS (TTM)
$0.24
52W Low $19.16High $48.25

Volume 0.91M

Average 0.64M

AORT Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Artivion, Inc.NYSE: AORT

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow growth accelerates

Q1 FY2026 investing cash flow of $10.5M (cash outflow) rose 188.7% year over year, ahead of the +73.3% change in trailing-twelve-month investing cash flow. Sequentially, it fell 65.6% from the prior quarter. Over 3 fiscal years it compounded at +57.7% a year.

Context

  • Investing cash flow amounted to 9.5% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Investing cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +188.7% holds above the trailing-twelve-month pace of +73.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.5M-65.6% QoQ
Last fiscal yearDec 2025
-$42.04M+49.1% YoY
LTMMar 2026
-$48.91M+73.3% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+188.7%——
1 year+49.1%——
3-year CAGR+57.7%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(42.04M) USD
Year-over-year change
-49.1%

Investing Cash Flow vs competitors

How AORT compares with its peers on the latest reported figures

  • AORT's LTM Mar 2026 investing cash flow of $48.91M is the 6th largest of the 11 companies compared; the peer median is $50.51M.
  • Its year-over-year change of +73.3% is the 5th highest of 11, against a peer median of -19.5%.
  • Investing cash flow amounts to 10.7% of revenue for AORT, versus a peer median of 3.5%.
AORT Competitors Peer median
Investing Cash Flow for AORT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COGTCogent Biosciences, Inc.LTM Jun 2026$499.99M -349.8%+47.4%—
BKDBrookdale Senior Living Inc.LTM Sep 2026$239.47M -56.9%+89.1%8.1%
ARDTArdent Health Partners, LLCLTM Mar 2026$219.01M +3.3%—3.4%
ITGRInteger Holdings CorporationLTM Jul 2026$116.32M -45.0%+10.5%6.3%
LFSTLifeStance Health Group, Inc.LTM Jun 2026$53M +101.7%-36.3%3.3%
AORTArtivion, Inc.LTM Mar 2026$48.91M +73.3%+57.7%10.7%
ADUSAddus HomeCare CorporationLTM Jun 2026$48.01M -86.5%-32.7%3.3%
INSPInspire Medical Systems, Inc.LTM Jun 2026$31.26M -42.3%—3.5%
LQDALiquidia CorporationLTM Jun 2026$23.52M +197.2%+121.0%5.2%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$10.43M +142.7%+52.2%3.2%
SSIISS Innovations International, Inc.LTM Mar 2026$2.84M +101.9%—5.9%
Peer median (excluding AORT) $50.51M-19.5%+47.4%3.5%

Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.83M)(19.19M)(30.69M)(13.36M)9.77M
Depreciation & Amortization23.98M22.44M23.08M24.21M22.46M
Deferred Income Tax(4.47M)(1.72M)(1.39M)(1.51M)37K
Stock-Based Compensation10.71M12.34M14.42M14.24M24.39M
Change in Working Capital(33.23M)(25.94M)(16.19M)(17.24M)(22.16M)
Accounts Receivables(11.56M)(13.34M)(4.05M)(15.4M)(7.27M)
Inventory(18.38M)(8.4M)(14.36M)(6.14M)(15.28M)
Accounts Payables(1.89M)(1.96M)1.68M9.5M2.18M
Other Working Capital(1.4M)(2.23M)535K(5.21M)(1.8M)
Other Non-Cash Items15.26M6.91M29.6M15.9M3.64M
Operating Cash Flow(2.59M)(5.15M)18.83M22.24M38.13M
Capital Expenditures(13.09M)(10.72M)(7.43M)(11.19M)(39.04M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments19M0000
Other Investing Activities(249K)06.93M(17M)(3M)
Investing Cash Flow5.66M(10.72M)(502K)(28.19M)(42.04M)
Debt Repayment(3.09M)(2.75M)(2.77M)(358K)(2.46M)
Common Stock Issued0005.73M13.07M
Common Stock Repurchased(1.91M)(1.8M)(559K)00
Dividends Paid00000
Other Financing Activities(7.22M)2.91M4.2M(3.17M)2.42M
Financing Cash Flow(12.22M)(1.64M)865K2.2M13.03M
Effect of Forex Changes2.2M1.85M401K(1.73M)2.32M
Net Change in Cash(6.95M)(15.66M)19.59M(5.48M)11.45M
Free Cash Flow(15.68M)(15.87M)11.4M11.05M(911K)

Artivion, Inc.

NYSE:AORT

Intrinsic Alpha fair value

Locked

Current Price

$18.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.